Meningococcal vaccine groups A and C conjugate - GlaxoSmithKline
Latest Information Update: 08 Sep 2006
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Meningococcal group A infections; Meningococcal group C infections
Most Recent Events
- 06 Sep 2006 Discontinued - Phase-II for Meningococcal group A infections in Europe (unspecified route)
- 06 Sep 2006 Discontinued - Phase-II for Meningococcal group C infections in Europe (unspecified route)
- 13 Mar 2001 Phase-II clinical trials for Meningococcal group A infections in Europe (Unknown route)